Artivion (AORT) Q2 2026 earnings — TrendMatrix coverage

Reported EPS

$0.13

Estimate

$0.10

Surprise

+34.5%

Score at report (before → after)

6.2 → 6.0/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Artivion (AORT) beat the $0.10 estimate with diluted EPS of $0.13 — a large 34.5% upside surprise. TrendMatrix's engine moved from Buy (Wait) (6.2/10) to Hold at 6.0/10 after the report — the engine's score fell despite the beat.

TrendMatrix currently rates AORT Sell at 5.5/10.

2 of the last 4 quarters beat the estimate; this quarter's +34.5% surprise compares with a +0.3% four-quarter average. Next scheduled report: 2026-11-05.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$25.35

Price target

$36.67

Stop

$23.67

Upside to target

+44.7%

Reward-to-risk

6.0:1

Model outputs from TrendMatrix’s engine as of 2026-09-17 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Medical Devices

Market cap

$1.24B

P/E (fwd)

33.9

52-week range

$19.16–$48.25

Off 52-week high

47.5%

RSI (14)

28

Volume vs avg

1.08×

Score today

5.5/10